Foundation Medicine teams up with Novartis for cancer diagnostics

The recently IPO'd Foundation Medicine ($FMI) has expanded its relationship with Novartis ($NVS), lending out its gene-profiling technology to help the drugmaker develop cancer treatments. Under the deal, Foundation will team up with Novartis to evaluate oncology candidates, develop biological targets and recruit patients for clinical trials, the company said, using the technology behind its FoundationOne diagnostic. Article

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Atomwise and Velocity Pharmaceutical Development co-founded a company to carry AI-derived drugs through preclinical testing and into takeout deals.

Sera Prognostics has raised $36 million in funding to help commercialize its blood test for assessing the risk of premature births.